

[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
David Nierengarten Reiterated (ANAB) at Buy and Held Target at $28 on, Mar 9th, 2017
David Nierengarten of Wedbush, Reiterated "AnaptysBio, Inc." (ANAB) at Buy and Held Target at $28 on, Mar 9th, 2017.
David has made no other calls on ANAB in the last 4 months.
There is 1 other peer that has a rating on ANAB. Out of the 1 peers that are also analyzing ANAB, 0 agree with David's Rating of Hold.
This is the rating of the analyst that currently disagrees with David
- Kennen MacKay of "Credit Suisse" Initiated at Buy and Held Target at $34 on, Tuesday, February 21st, 2017
Contributing Sources
Similar Stocks and Investing Articles
[ Tue, Mar 07th 2017
] - WOPRAI
[ Thu, Nov 10th 2016
] - WOPRAI
[ Thu, Mar 03rd 2016
] - WOPRAI
[ Thu, Sep 17th 2015
] - WOPRAI
[ Mon, Mar 09th 2015
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Wed, Mar 13th 2013
] - WOPRAI
[ Mon, Mar 11th 2013
] - WOPRAI
[ Fri, Mar 02nd 2012
] - WOPRAI